Danish Start-Up ADCendo Takes Aim At Novel Cancer Target With Fresh Funds
Fully Funded Biotech Plans Proof-Of-Concept In Man by End-2025
Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.
